LivaNova PLC (NASDAQ:LIVN) Given Average Rating of "Hold" by Brokerages

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $66.20.

LIVN has been the subject of several research analyst reports. Mizuho boosted their target price on shares of LivaNova from $75.00 to $80.00 and gave the stock a "buy" rating in a research report on Thursday, May 2nd. Robert W. Baird boosted their target price on shares of LivaNova from $58.00 to $66.00 and gave the stock a "neutral" rating in a research report on Thursday, May 2nd. Needham & Company LLC reissued a "buy" rating and issued a $72.00 target price on shares of LivaNova in a research report on Wednesday, May 1st. StockNews.com raised shares of LivaNova from a "hold" rating to a "buy" rating in a research report on Thursday, April 25th. Finally, Barclays boosted their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an "equal weight" rating in a research report on Monday, February 26th.

LivaNova Stock Down 1.5 %

LIVN stock traded down $0.92 during trading on Friday, reaching $61.96. The stock had a trading volume of 309,256 shares, compared to its average volume of 633,745. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a current ratio of 3.17, a quick ratio of 2.71 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $3.36 billion, a P/E ratio of -103.27 and a beta of 0.92. The firm has a fifty day moving average price of $56.24 and a 200 day moving average price of $52.00.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The firm had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. During the same quarter in the previous year, the business posted $0.43 EPS. The firm's revenue was up 12.0% compared to the same quarter last year. On average, equities analysts anticipate that LivaNova will post 2.59 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of LIVN. Headlands Technologies LLC bought a new stake in shares of LivaNova during the 3rd quarter valued at about $72,000. Lazard Asset Management LLC acquired a new position in LivaNova during the 1st quarter valued at about $84,000. Picton Mahoney Asset Management acquired a new position in LivaNova during the 3rd quarter valued at about $91,000. Acadian Asset Management LLC acquired a new position in LivaNova during the 1st quarter valued at about $94,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in LivaNova during the 3rd quarter valued at about $217,000. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.